Ameera Shah-led pathology laboratory chain Metropolis Healthcare Ltd has approved the issuance of bonus shares in the ratio of 3:1 to eligible equity shareholders and the slump sale of its diagnostics services division to a wholly owned subsidiary.
As per the announcement, three equity shares will be issued for every one equity share held by shareholders as on the record date.
Separately, Metropolis has entered into a business transfer agreement with Metropolis Quality Solutions Pvt. Ltd. (MQSPL) for the slump sale of its External Quality Assessment Services (EQAS) division for ₹1.25 crore. The related-party transaction is expected to be completed within six months. There will be no change in the company’s shareholding pattern pursuant to the slump sale.
The transaction will enable the EQAS division to operate as a separate and independent unit, focusing on its core services with dedicated management and resources to drive efficiency, excellence, and growth.
EQAS is engaged in the diagnostics services business, while MQSPL operates in the healthcare technology space. During FY24, EQAS contributed ₹84 lakh, representing 0.07% of the company’s total standalone revenue.
Metropolis Healthcare reported a 34% year-on-year growth in consolidated net profit for the December quarter at ₹42 crore, driven by network expansion, improved service levels, and consistent execution across channels. Revenue from operations rose 26% to ₹406 crore. The results included an exceptional item of ₹9 crore related to the implementation of the New Labour Code.
Patient and test volumes grew 14% and 13%, respectively. B2C revenues increased 19%, while B2B revenues rose 35%. The TruHealth and Specialty portfolios recorded growth of 37% and 34%, respectively. Revenue per test and revenue per patient increased 11% and 10%, respectively. North India recorded revenue growth of 17%, while Tier III cities registered 16% growth and contributed 24% to overall revenues.
“Our strong Q3 and year-to-date performance reflects disciplined execution across the business. Growth has been broad-based, supported by strong momentum across our key segments, higher B2B contribution, and effective network expansion. Improved margins in a typically lean quarter highlight the strength of our operating model and productivity gains. With integration synergies from recent acquisitions progressing well and healthy demand trends, we remain confident of achieving our full-year growth and profitability objectives,” said Surendran Chemmenkotil, Managing Director, Metropolis Healthcare.
“As our genomics and advanced diagnostics platforms scale, we are building a science-led, resilient, and future-ready diagnostics institution that meaningfully advances clinical decision-making and delivers enduring value for patients, clinicians, and the wider healthcare ecosystem,” said Ameera Shah, Promoter and Executive Chairperson, Metropolis Healthcare.